Core Viewpoint - Anteris Technologies Global Corp. announced a significant capital raise, leading to a 52.17% increase in share price during after-hours trading, reaching $8.75, following a regular session close of $5.75, which was up 12.52% [1]. Group 1: Capital Raise Details - The company plans to conduct a $200 million underwritten public offering of common stock, with underwriters having a 30-day option to purchase an additional $30 million in shares at the offering price [2]. - Anteris has also agreed to sell up to $90 million in common stock to Medtronic plc through a private placement, with Medtronic set to acquire between 16% and 19.99% of shares outstanding after the public offering [3]. Group 2: Use of Proceeds - Proceeds from the capital raise will be utilized to support the DurAVR Transcatheter Heart Valve global pivotal trial for patients with severe aortic stenosis, as well as to expand manufacturing capacity and development for v2vmedtech, inc. [5]. Group 3: Trading Metrics and Analysis - Anteris has a market capitalization of $236.89 million, with its stock trading within a 52-week range of $2.34 to $8.79. Over the past 12 months, the stock has seen a decline of 2.21%, indicating ongoing challenges for the company [6]. - The stock is currently positioned at 52.9% of its 52-week range, nearing yearly highs, and has a Relative Strength Index (RSI) of 66.01, suggesting a positive price trend across all time frames [6][7].

As filed with the Securities and Exchange Commission on December 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification Number) 18000 Devonshire St. Northridge, CA 91325 (763) 514-4000 (Address, including zip ...

Core Insights - Clearfield, Inc. has announced the election of Rebecca Seidel and Kathleen Skarvan to its Board of Directors, effective December 10, 2025 [1][2] - The new board members are expected to enhance the board's collective strength and support Clearfield's long-term growth [2] Board Member Contributions - Rebecca Seidel brings over 20 years of experience in MedTech, currently serving as Senior Vice President and President of Cardiac Ablation Solutions at Medtronic, overseeing a $1 billion revenue business [3] - Kathleen Skarvan has extensive experience as a Board Director and CEO, previously serving as President and CEO of Electromed, Inc., and has a strong background in high technology executive roles [3] Company Overview - Clearfield, Inc. specializes in designing, manufacturing, and distributing fiber optic management solutions, playing a critical role in enabling broadband operators to close the digital divide [4] - The company is headquartered in Minneapolis, MN, and deploys over a million fiber ports each year [4]

Market Overview - The China biopsy devices market is projected to grow from approximately US$ 612.62 million in 2024 to about US$ 1.13 billion by 2033, reflecting a compound annual growth rate (CAGR) of 7.06% during the period from 2025 to 2033 [2][16]. Growth Drivers - The rising prevalence of cancer in China, with an estimated 4,824,700 new cases and 2,574,200 cancer-related deaths in 2022, is significantly driving the demand for biopsy devices [4]. - Technological advancements in biopsy devices, such as ultrasound-guided systems and robotic-assisted devices, are enhancing diagnostic precision and patient comfort, thereby expanding the market [5]. - The expansion of healthcare infrastructure, including the establishment of high-tech diagnostic centers and easing of foreign investment restrictions, is improving access to advanced biopsy technologies across various regions [6]. Challenges - High costs associated with advanced biopsy technologies pose a significant barrier to widespread adoption, particularly in underdeveloped regions where budget constraints limit healthcare facilities' ability to invest [7]. - A limited number of skilled professionals trained to operate sophisticated biopsy devices and interpret data is hindering effective utilization, especially in rural areas [8]. Market Segmentation - The market for needle-based guns biopsy devices is experiencing substantial growth due to their minimally invasive nature and high precision in tissue sample acquisition [9]. - The breast biopsy devices market is expanding due to the increasing incidence of breast cancer and the growing awareness of the need for early diagnosis, with innovations like vacuum-assisted biopsy systems gaining prominence [10][11]. - The lung biopsy devices market is rapidly growing, driven by rising lung cancer cases linked to environmental pollution and smoking, with advanced imaging-guided techniques enhancing diagnostic accuracy [12]. - The CT scan biopsy devices market is also growing, fueled by the reliance on CT-guided biopsies for their accuracy in diagnosing deep-seated lesions [13]. - The MRI-guided biopsy devices market is witnessing significant growth due to the high-resolution imaging capabilities of MRI technology, which improves diagnostic outcomes [14]. Key Players - Major companies in the biopsy devices market include Cardinal Health, Hologic, Danaher, Becton, Dickinson and Company, Boston Scientific, Medtronic, and Olympus [18].

Core Insights - The medical sector is increasingly adopting artificial intelligence (AI) for drug synthesis, precise measurement, and faster diagnosis [1] - AI applications in healthcare are enhancing diagnostics, treatment, and operational efficiency, with a projected market value of $95.65 billion by 2025 [4] AI Applications in Healthcare - Generative AI and surgical robotics are being utilized in diagnostic settings to detect image abnormalities that may be missed by human eyes [2] - AI is also improving electronic health records, predictive analytics, and real-time alerting systems [2] Focus on Healthcare Giants - Five healthcare companies are highlighted for their extensive AI applications: Medtronic plc (MDT), Eli Lilly and Co. (LLY), Boston Scientific Corp. (BSX), Novartis AG (NVS), and Abbott Laboratories (ABT) [3][6] Company-Specific Insights Medtronic plc (MDT) - MDT is integrating AI into surgical systems and has developed an AI-powered surgical video management platform [8] - The GI Genius project enhances colorectal cancer detection, increasing survivability by identifying polyps [9] - Expected revenue and earnings growth rates for MDT are 3.4% and 5%, respectively [11] Eli Lilly and Co. (LLY) - LLY focuses on cardiometabolic health, neuroscience, oncology, and immunology, with a strong portfolio in diabetes treatment [12][13] - The company collaborates with OpenAI and invested $409 million in Genetic Leap for AI-driven drug discovery [14] - Expected revenue and earnings growth rates for LLY are 33% and 80.7%, respectively [15] Boston Scientific Corp. (BSX) - BSX is investing in AI-driven health IT solutions to enhance healthcare delivery and clinical outcomes [16] - The company is also focusing on AI-enhanced medical education tools and patient engagement solutions [17] - Expected revenue and earnings growth rates for BSX are 13.8% and 13.6%, respectively [18] Novartis AG (NVS) - NVS is applying AI in generative chemistry, AE brain, and AI nurse applications to innovate patient technologies [19][20] - Expected revenue and earnings growth rates for NVS are 4.1% and 8.5%, respectively [21] Abbott Laboratories (ABT) - ABT utilizes AI for advanced medical imaging and predictive algorithms for heart attack prevention [22] - The company holds a strong position in point-of-care testing across various healthcare areas [23] - Expected revenue and earnings growth rates for ABT are 5.7% and 10.3%, respectively [23]

Market Overview - The global anesthesia devices market is estimated to be valued at US$17.1 billion in 2024 and projected to reach US$27.3 billion by 2030, registering a CAGR of 8.1% from 2024 to 2030 [1][14]. Market Drivers - The market is driven by the increasing number of surgical procedures, particularly in cardiology, neurology, and orthopedics, alongside the rising prevalence of chronic illnesses and age-related conditions in the geriatric population [2][4]. - High-impact injuries from accidents have led to a surge in orthopedic surgeries requiring anesthesia [2]. Technological Advancements - Innovations in anesthesia delivery systems, such as real-time monitoring and automated dosing, are enhancing patient safety and operational efficiency [4][10]. Regional Analysis - North America holds the largest share of the global anesthesia devices market at 40.8% in 2024, driven by a sophisticated healthcare system and high rates of surgical procedures [5]. - The Asia-Pacific region is experiencing the fastest growth, with a projected CAGR of over 10% during 2024-2030, supported by improvements in healthcare infrastructure and rising surgical numbers [6]. Product Segmentation - The market is segmented into anesthesia delivery machines, disposables & accessories, monitors, and anesthesia information management systems (AIMS), with anesthesia delivery machines accounting for 37.5% of the market share in 2024 [7]. - The anesthesia monitors segment is projected to grow the fastest with a CAGR of 9.4% from 2024 to 2030 [8]. Application Segmentation - The orthopedics segment leads the market with a 22.2% share in 2024, attributed to the rising incidence of orthopedic conditions [9]. - Cardiology is the most rapidly expanding segment within the anesthesia devices market, with a CAGR of 9.7% from 2024 to 2030, driven by the prevalence of cardiovascular illnesses and an increasing number of cardiac surgeries [10].

Core Insights - Medtronic plc (MDT) presented the two-year results of the SMART trial, the largest international head-to-head trial comparing TAVR options for patients with aortic stenosis and small aortic annulus at the CRT 2025 conference [1][2][6] Company Performance - The SMART trial results indicate that the Evolut TAVR valve outperforms the SAPIEN TAVR valve, showing significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less hemodynamic structural valve dysfunction [5][6] - Following the news, MDT's share price increased by 0.01% to $94.51, reflecting positive market sentiment towards the company's Structural Heart business [3] - Medtronic has a market capitalization of $121.20 billion and has delivered an average earnings surprise of 1.75% over the last four quarters [4] Industry Outlook - The global transcatheter aortic valve replacement market is projected to grow at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2030, driven by the rising prevalence of aortic stenosis, increasing preference for minimally invasive procedures, and a growing geriatric population [7]

Core Insights - The SMART Trial presents the two-year results of the largest international head-to-head randomized control trial comparing Evolut and SAPIEN TAVR devices, primarily enrolling women with small aortic annuli [1][3][4] - Evolut TAVR demonstrated superior valve performance and significantly less bioprosthetic valve dysfunction (BVD) compared to SAPIEN TAVR, which is critical for patients with small aortic annuli [2][4][6] Company Overview - Medtronic plc is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across 150 countries, focusing on innovative technologies that address challenging health problems [6][7] Industry Context - Aortic stenosis affects approximately 1.5 million people in the U.S., with a significant portion of the global market having small aortic annuli, necessitating tailored valve selection [5] - The SMART Trial's findings are expected to inform and personalize treatment decisions for patients with symptomatic severe aortic stenosis [2][4]

Core Points - Medtronic plc's board of directors approved a cash dividend of $0.70 per ordinary share for the fourth quarter of fiscal year 2025, consistent with a previous dividend increase announced in May 2024 [1] - Medtronic has a strong history of dividend payments, having increased its annual dividend for 47 consecutive years, and is part of the S&P 500 Dividend Aristocrats index [1] - The dividend will be payable on April 11, 2025, to shareholders of record as of March 28, 2025 [1] Company Overview - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges through innovative solutions [2] - The company's mission is to alleviate pain, restore health, and extend life, supported by a global workforce of over 95,000 employees across more than 150 countries [2] - Medtronic's technologies and therapies address 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems [2]

Core Insights - The U.K. surgical pledgets market is projected to grow significantly, driven by advancements in surgical technologies and increased healthcare infrastructure investments [1][2][3] Market Overview - The market was valued at approximately US$15.3 million in 2023 and is expected to exceed US$27.5 million by 2034, with a CAGR of 5.5% from 2024 to 2034 [2][16][24] - Surgical pledgets are critical in enhancing surgical repairs by distributing load and reducing tissue tear risks, particularly in cardiovascular, general, and orthopedic surgeries [3][9][10] Key Market Drivers - The rising prevalence of cardiovascular disorders, affecting nearly 7.6 million individuals in the U.K., is a significant driver for the demand for surgical pledgets [7][11] - The geriatric population is growing, with over 11 million individuals aged 65 and above in England and Wales as of 2021, increasing the need for effective surgical interventions [12] - Continuous advancements in surgical technologies and product innovations are enhancing the safety and effectiveness of surgical pledgets [8][13] Competitive Landscape - Key players in the U.K. surgical pledgets market include Becton, Dickinson, and Company (BD), Medtronic plc, B. Braun Melsungen AG, and Ethicon, Inc. [4][27] - Companies are engaging in strategic partnerships and technological advancements to strengthen their market positions [4][8] Recent Developments - B. Braun entered an agreement with IDENTI Medical to enhance surgical sutures inventory management [5] - Ethicon launched antibacterial sutures that reduce surgical site infections by 30% [5] - DeRoyal Industries collaborated with researchers to innovate compression wound care therapy [6] Market Segmentation - The market is segmented by application, with cardiovascular surgeries being the largest segment due to the high number of heart-related surgeries performed annually [21] - Material types include Teflon and polyester surgical pledgets, with Teflon known for durability and biocompatibility [21] Future Outlook - The market is expected to grow steadily, driven by the increasing number of surgeries, technological advancements, and an aging population [21][22]